Gastrointestinal Drugs Market Research Report by Drug Category (Acid Neutralizers, Anti-Inflammatory, Antiemetic and Antinauseants, Biologics, and Laxatives and Anti-diarrheal), by Route of Administration (Oral, Parenteral, and Rectal), by Disease Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
The Global Gastrointestinal Drugs Market is expected to grow from USD 44,092.61 Million in 2019 to USD 58,277.04 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 4.75%.
Market Segmentation & Coverage: This research report categorizes the Gastrointestinal Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Category, the Gastrointestinal Drugs Market studied across Acid Neutralizers, Anti-Inflammatory, Antiemetic and Antinauseants, Biologics, and Laxatives and Anti-diarrheal.
Based on Route of Administration, the Gastrointestinal Drugs Market studied across Oral, Parenteral, and Rectal.
Based on Disease Type, the Gastrointestinal Drugs Market studied across Gastroesophageal Reflux Disorder and Irritable Bowel Syndrome.
Based on End User, the Gastrointestinal Drugs Market studied across Hospital Pharmacies and Retail Pharmacies.
Based on Geography, the Gastrointestinal Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Gastrointestinal Drugs Market including Abbott Laboratories, AbbVie Inc., Allergan Plc, AstraZeneca plc, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim GmbH, Eisai Co., Ltd., GlaxoSmithKline Plc., Janssen Biotech Inc., Janssen Biotech, Inc., Johnson & Johnson, Sanofi S.A, Takeda Pharmaceutical Company Limited, and ZERIA Pharmaceutical Co.,Ltd..
FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Gastrointestinal Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as: 1. What is the market size and forecast of the Global Gastrointestinal Drugs Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Gastrointestinal Drugs Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Gastrointestinal Drugs Market? 4. What is the competitive strategic window for opportunities in the Global Gastrointestinal Drugs Market? 5. What are the technology trends and regulatory frameworks in the Global Gastrointestinal Drugs Market? 6. What are the modes and strategic moves considered suitable for entering the Global Gastrointestinal Drugs Market?
Our reports have been used by over 10K customers, including:
Gastric Ulcers - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H2 2020, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining...
The global constipation treatment market is expected to reach US$ 13,386.19 million in 2027 from US$ 8,533.89 million in 2019. The market is estimated to grow with a CAGR of 5.9% from 2020-2027. The increasing number of FDA approvals and drug development activities are likely to accelerate the market’s growth during the forecast period.The...
122 pages •
By Euromonitor International
• Oct 2020
Consumer health is expected to see slightly higher current value growth in 2020 than was seen the previous year. One of the factors dictating growth in this year is expected to be COVID-19. As news about the virus emerged in the country, consumers began panic-buying at the beginning of March, stockpiling certain consumer health products, such...
108 pages •
By Euromonitor International
• Oct 2020
Consumer health is proving to be among the most resilient industries that the analyst covers in terms of COVID-19’s impact on it. Many of the products are considered as essential, with consumers not likely to stop using them, even during a global pandemic. Some of the industry’s products have actually been seeing stronger sales as they are...
Antacids Market Research Report by Formulation (Liquid, Powder, and Tablet), by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents, and Proton Pump Inhibitor), by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Antacids Market is expected to grow from USD 6,602.69...
The global anal irrigation system market is expected to reach US$ 387,942.3 thousand by 2027 from US$ 323,039.0 thousand in 2019; it is estimated to grow at a CAGR of 2.5% from 2020 to 2027. The growth of the market is attributed to the rising incidence of colorectal cancer and inflammatory bowel diseases, rising geriatric population, and...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.